AR123474A1 - Vesículas de la membrana externa - Google Patents
Vesículas de la membrana externaInfo
- Publication number
- AR123474A1 AR123474A1 ARP210102509A ARP210102509A AR123474A1 AR 123474 A1 AR123474 A1 AR 123474A1 AR P210102509 A ARP210102509 A AR P210102509A AR P210102509 A ARP210102509 A AR P210102509A AR 123474 A1 AR123474 A1 AR 123474A1
- Authority
- AR
- Argentina
- Prior art keywords
- gonococcal
- bacterium
- polypeptide
- expression
- function
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title abstract 3
- 241000894006 Bacteria Species 0.000 abstract 10
- 108020004999 messenger RNA Proteins 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 230000003247 decreasing effect Effects 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 101150031313 rmp gene Proteins 0.000 abstract 2
- 102000057234 Acyl transferases Human genes 0.000 abstract 1
- 108700016155 Acyl transferases Proteins 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/36—Neisseria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere al campo de las composiciones de vacunas de neisseria (en particular las composiciones de vacunas gonocócicas) y al uso detales composiciones en medicina. Más en particular, la presente invención se refiere a gonococos genéticamente modificados de la cepa FA1090 y vesículas de la membrana externa obtenidas a partir de los mismos. La invención también proporciona un proceso para la preparación de los gonococos genéticamente modificados de la invención, así como también composiciones inmunogénicas y vacunas que comprenden las vesículas de la membrana externa de la invención. Reivindicación 1: Una bacteria gonocócica genéticamente modificada de la cepa FA1090, que comprende modificaciones genéticas que: a. disminuyen o anulan la expresión y/o función del gen, ARNm y/o polipéptido de lauroil aciltransferasa (lpxl1) de biosíntesis del lípido A; y b. disminuyen o anulan la expresión y/o función del gen, ARNm y/o polipéptido de la proteína modificable por reducción (rmp). Reivindicación 6: Un proceso para la producción de la bacteria gonocócica de acuerdo con las reivindicaciones 1 a 5, el proceso comprende: a) la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen lpxl1 en una bacteria gonocócica FA1090 para producir una primera bacteria gonocócica FA1090 y la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen rmp de la primera bacteria gonocócica FA1090 para producir una segunda bacteria gonocócica FA1090; o b) la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen rmp de la primera bacteria gonocócica FA1090 para producir una primera bacteria gonocócica FA1090 y la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen lpxl1 de la primera bacteria gonocócica FA1090 para producir una segunda bacteria gonocócica FA1090.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20195709 | 2020-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123474A1 true AR123474A1 (es) | 2022-12-07 |
Family
ID=72473456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102509A AR123474A1 (es) | 2020-09-11 | 2021-09-09 | Vesículas de la membrana externa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230321213A1 (es) |
| EP (1) | EP4211147A1 (es) |
| JP (1) | JP2023541876A (es) |
| KR (1) | KR20230066041A (es) |
| CN (1) | CN116096871A (es) |
| AR (1) | AR123474A1 (es) |
| AU (2) | AU2021339930B2 (es) |
| BR (1) | BR112023003571A2 (es) |
| CA (1) | CA3194346A1 (es) |
| IL (1) | IL300922A (es) |
| MX (1) | MX2023002786A (es) |
| WO (1) | WO2022053535A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202305851D0 (en) * | 2023-04-20 | 2023-06-07 | Univ Oxford Innovation Ltd | Composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| EP2185576A4 (en) * | 2007-08-02 | 2011-01-12 | Childrens Hosp & Res Ct Oak | FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES |
| ES2759484T3 (es) | 2010-09-10 | 2020-05-11 | Glaxosmithkline Biologicals Sa | Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo |
-
2021
- 2021-09-09 KR KR1020237011635A patent/KR20230066041A/ko active Pending
- 2021-09-09 EP EP21773104.1A patent/EP4211147A1/en active Pending
- 2021-09-09 BR BR112023003571A patent/BR112023003571A2/pt unknown
- 2021-09-09 US US18/025,273 patent/US20230321213A1/en active Pending
- 2021-09-09 CN CN202180062246.XA patent/CN116096871A/zh active Pending
- 2021-09-09 AU AU2021339930A patent/AU2021339930B2/en active Active
- 2021-09-09 JP JP2023515724A patent/JP2023541876A/ja active Pending
- 2021-09-09 AR ARP210102509A patent/AR123474A1/es not_active Application Discontinuation
- 2021-09-09 CA CA3194346A patent/CA3194346A1/en active Pending
- 2021-09-09 IL IL300922A patent/IL300922A/en unknown
- 2021-09-09 MX MX2023002786A patent/MX2023002786A/es unknown
- 2021-09-09 WO PCT/EP2021/074744 patent/WO2022053535A1/en not_active Application Discontinuation
-
2024
- 2024-08-29 AU AU2024216413A patent/AU2024216413A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230066041A (ko) | 2023-05-12 |
| US20230321213A1 (en) | 2023-10-12 |
| AU2021339930A1 (en) | 2023-04-20 |
| EP4211147A1 (en) | 2023-07-19 |
| JP2023541876A (ja) | 2023-10-04 |
| CN116096871A (zh) | 2023-05-09 |
| AU2024216413A1 (en) | 2024-09-19 |
| IL300922A (en) | 2023-04-01 |
| MX2023002786A (es) | 2023-05-30 |
| BR112023003571A2 (pt) | 2023-04-04 |
| CA3194346A1 (en) | 2022-03-17 |
| WO2022053535A1 (en) | 2022-03-17 |
| AU2021339930B2 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012022688A2 (pt) | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão | |
| Mazzini et al. | Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1+ macrophages to CD103+ dendritic cells | |
| US9549970B2 (en) | Methods for producing yeast-based vaccines | |
| ECSP22052002A (es) | Métodos de cultivo de células, preparación de hidrolizado a partir de células y aplicaciones de los mismos | |
| BR112012022800A2 (pt) | composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica | |
| EP4226938A2 (en) | Coronavirus vaccine | |
| AR061333A1 (es) | Composiciones de vacuna de la neisseria | |
| MX2022009018A (es) | Nanoparticulas lipidas. | |
| MX2021011418A (es) | Metodos de produccion de bioconjugados de polisacaridos de e. coli o- antigeno, sus composiciones y metodos de utilizacion. | |
| MX2023005696A (es) | Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas. | |
| AR123474A1 (es) | Vesículas de la membrana externa | |
| BRPI0411519A (pt) | membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica | |
| EP4469080A2 (en) | Coronavirus vaccine | |
| JP2020510726A (ja) | 低下した反応源性を有するｌｐｓを含むボルデテラワクチン | |
| US12208136B2 (en) | Coronavirus vaccine | |
| CN117157400A (zh) | 用于编码核酸的治疗潜力的效力测定 | |
| AR122023A1 (es) | Péptidos y métodos para el tratamiento de esclerosis múltiple | |
| Mahony et al. | Can the revolution in mRNA-based vaccine technologies solve the intractable health issues of current ruminant production systems? | |
| Chen et al. | Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine | |
| CL2023001142A1 (es) | Composiciones y métodos para la vacunación contra neisseria gonorrhoeae | |
| ES2550938T3 (es) | Medicamentos y métodos para el tratamiento de mesotelioma | |
| WO2023104114A8 (en) | Rna formulations and lipids | |
| BR0316687A (pt) | Composição e adjuvante vacinal e método para a obtenção de estruturas cocleares a partir de vesìculas de membrana externa de organismos vivos | |
| MX2024007047A (es) | Formulaciones de arn y lipidos. | |
| Meza et al. | Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |